Darunavir Ethanolate – Anti-Retroviral / Anti-HIV Therapeutic

Darunavir Ethanolate – Anti-Retroviral / Anti-HIV Therapeutic

Darunavir EthanolateDarunavir Ethanolate CAS# 635728-49-3 is a second-generation protease inhibitor (PIs), designed specifically to overcome problems with the older agents in this class, such as indinavir. Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutations to PIs. Darunavir is always used in combination with ritonavir (Norvir) and other anti-HIV medicines.

We are proud to present to you this product for the research and development of new formulations in the Anti-Retroviral / Anti-HIV therapeutic category.

It is in our best interest to promote and to further your ongoing research and/or product development efforts. All the enumerated API’s are produced strictly following cGMP guidelines and regulations. It would be our pleasure to supply you with Darunavir Ethanolate, as well as any other new molecules that may be required.

Click here to inquire about price and availability >

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service